Market Place
Sourcing Support
Quantum BioPharma Sues Banks for Stock Manipulation
25 Nov 2024 //
ACCESSWIRE
Quantum Biopharma To Complete Debt Settlements And Provides Update
23 Aug 2024 //
ACCESSWIRE
FSD Pharma Updates On Celly Nutrition`s Unbuzzd Launch
09 Aug 2024 //
ACCESSWIRE
FSD receives HERC approval for phase-1 doses clinical trial in Australia
29 Jun 2024 //
PHARMABIZ
FSD Pharma Wins Final Judgment to Confirm Arbitration Award of $3,059,998
28 Jun 2024 //
ACCESSWIRE
FSD Pharma provides Corporate Update
28 Jun 2024 //
ACCESSWIRE
FSD Pharma Receives Approval for Phase-1 Multiple Ascending Doses Clinical Trial
27 Jun 2024 //
ACCESSWIRE
FSD Pharma Options USC Dietary Supplement Tech For unbuzzd, Other Apps
13 Jun 2024 //
ACCESSWIRE
FSD Pharma: IRB Nod To Study Unbuzzd In Acute Alcohol Intoxication
04 Jun 2024 //
ACCESSWIRE
FSD Pharma Wins $3M+ Arbitration Award Against Dr. Bokhari
31 May 2024 //
ACCESSWIRE
FSD Pharma: Trial Protocol For Unbuzzd In Alcohol Intoxication Submitted
28 May 2024 //
ACCESSWIRE
FSD Pharma Provides Corporate Update
24 May 2024 //
ACCESSWIRE
FSD Pharma Provides Update on Celly Nu`s New Packaging for unbuzzd(TM)
16 May 2024 //
ACCESSWIRE
FSD Pharma Phase 1 Trial For Lucid-MS In Australia
07 May 2024 //
ACCESSWIRE
FSD Pharma, ASPI To Assess unbuzzd`s Safety, Efficacy In Alcohol Trial
30 Apr 2024 //
ACCESSWIRE
FSD Pharma Updates on Celly Nu`s unbuzzd™ Partnership
25 Apr 2024 //
ACCESSWIRE
FSD Pharma Updates On Celly Nu`s unbuzzd Launch
22 Apr 2024 //
ACCESSWIRE
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss
17 Apr 2024 //
ACCESSWIRE
FSD Updates Celly Alcohol Metabolism Product Investment
15 Apr 2024 //
ACCESSWIRE
FSD Pharma Announces Filing of Year-End 2023 Results
01 Apr 2024 //
ACCESSWIRE
FSD Agreement With iNGENu To Conduct a Study Doses of Lucid-21-302 in Adults
27 Mar 2024 //
ACCESSWIRE
FSD Pharma Submits Ph1b Trial Application for Proprietary Beverage unbuzzd(TM)
11 Mar 2024 //
ACCESSWIRE
FSD Pharma Presents Positive Results on Phase-1 study of Lucid-21-302
05 Mar 2024 //
ACCESSWIRE
FSD Pharma Announces Debt Settlement
28 Feb 2024 //
ACCESSWIRE
FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial
26 Feb 2024 //
ACCESSWIRE
FSD Pharma Announces US ATM Offering
16 Feb 2024 //
ACCESSWIRE
FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Board of Directors
29 Jan 2024 //
ACCESSWIRE
Safety Shot Responds to FSD Pharma™s 3rd unauthorized Tagging of its Stock
17 Jan 2024 //
GLOBENEWSWIRE
FSD Pharma Files Shelf Prospectus to Replace Expired Base Shelf Prospectus
22 Dec 2023 //
ACCESSWIRE
FSD Pharma Inc. Obtains Final Order for Plan of Arrangement
27 Nov 2023 //
ACCESSWIRE
FSD Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.
21 Nov 2023 //
ACCESSWIRE
FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant
17 Nov 2023 //
ACCESSWIRE
FSD Files Supplement to Management Information Circular with Special Meeting
15 Nov 2023 //
ACCESSWIRE
FSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders
07 Nov 2023 //
ACCESSWIRE
FSD Pharma Files Preliminary Base Shelf Prospectus to Replace Shelf Prospectus
06 Nov 2023 //
ACCESSWIRE
FSD Pharma Files Management Information Circular for Arrangement with Celly Nu
23 Oct 2023 //
ACCESSWIRE
Brüush Announces Notice from Nasdaq for Continued Listing
05 Oct 2023 //
ACCESSWIRE
FSD Pharma Wins $2.8M Dollar Award Plus Accruing Interest from Dr. Raza Bokhari
04 Oct 2023 //
ACCESSWIRE
FSD announces Interim Results from First-in-Human Clinical Trial of Lucid-MS
18 Sep 2023 //
ACCESSWIRE
FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness
25 Aug 2023 //
BUSINESSWIRE
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023
15 Aug 2023 //
ACCESSWIRE
Syneos didn`t hold up its end of the deal in enrollment for FSD Pharma`s trial
18 Jul 2023 //
ENDPTS
FSD Appoints Zeeshan Saeed as CEO, Anthony Durkacz to Serve as Co-Chairman
04 Jul 2023 //
BUSINESSWIRE
InvestmentPitch Media Video Discusses FSD Pharma™s Granting of Exclusive Rights
23 Jun 2023 //
GLOBENEWSWIRE
P3 Health Partners Names William Bettermann as Chief Operating Officer
20 Jun 2023 //
BUSINESSWIRE
FSD Pharma Appoints Doctor Eric Hoskins to Board of Directors
25 May 2023 //
BUSINESSWIRE
FSD Announces Receipt of Court Action and Update on Spin-Out and Distribution
12 May 2023 //
BUSINESSWIRE
FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari
11 May 2023 //
BUSINESSWIRE
FSD completes first cohort dosing in multiple sclerosis drug trial
11 May 2023 //
CLINICAL TRIALS ARENA
FSD Pharma Completes Dosing of First Cohort in PhI Trial of Lucid-MS, a New Drug
10 May 2023 //
BUSINESSWIRE
FSD Pharma completes dosing of first cohort in Phase I trial of Lucid-MS
10 May 2023 //
INDIANPHARMAPOST
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
08 May 2023 //
BUSINESSWIRE
FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects
17 Apr 2023 //
BUSINESSWIRE
FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders
12 Apr 2023 //
BUSINESSWIRE
FSD Pharma Announces Filing of Year-End 2022 Results
31 Mar 2023 //
BUSINESSWIRE
FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors
30 Mar 2023 //
BUSINESSWIRE
FSD Pharma Announces Its Entity Receives Approval to Proceed With PI Trial of Lucid-201
22 Mar 2023 //
BUSINESSWIRE
Original “Shark” & Iconic Entrepreneur Kevin Harrington Joins FSD Advisory Board
28 Feb 2023 //
BUSINESSWIRE
